<button id="eiezk"><video id="eiezk"></video></button>

產(chǎn)品名稱

Tivozanib - AV 951 | KRN 951

產(chǎn)品貨號

Axon 1717 CAS [475108-18-0] MF C22H19ClN4O5MW 454.86 Purity: 98% Moderately soluble in DMSO Description A highly potent and orally available tyrosine kinase inhibitor (TKI), targeting VEGFR1, 2 and 3, c-KIT and PDGFR (IC50: 0.21, 0.16, 0.24, 1.63 and 1.72 nM, respectively) References Certificates Categories Extra info K Nakamura et al. KRN951, a Highly Potent Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases, Has Antitumor Activities and Affects Functional Vascular Properties. Cancer Res. 2006, 66(18), 9134-9142. ? Eri Taguchi et al. Anti-tumor activity and tumor vessel normalization by the vascular endothelial growth factor receptor tyrosine kinase inhibitor KRN951 in a rat peritoneal disseminated tumor model. Cancer Sci. 2008, 99(3), 623.? ? C Campas et al. Tivozanib. Drugs Fut. 2009, 34(10), 793. Certificate of Analysis Material Safety Data Sheet Angiogenesis Cell Signaling & Oncology VEGFR RTK class IV; EC 2.7.10.1 VEGFR1, 2, and 3 tyrosine kinase inhibitor Chemical name 1-(2-chloro-4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-3-(5-methylisoxazol-3-yl)urea Parent CAS No. [475108-18-0] Order Size Unit Price Stock 5 mg €99.00 In Stock

產(chǎn)品價格

現(xiàn)貨詢價，電話：010-67529703

產(chǎn)品規(guī)格

產(chǎn)品品牌

axonmedchem

產(chǎn)品概述

產(chǎn)品詳情

Tivozanib - AV 951 | KRN 951

Based on 15 reference(s) in Google Scholar 8 10 15

Axon 1717

CAS [475108-18-0]

MF C22H19ClN4O5
MW 454.86

Purity: 98%
Moderately soluble in DMSO

Tivozanib

Description

A highly potent and orally available tyrosine kinase inhibitor (TKI), targeting VEGFR1, 2 and 3, c-KIT and PDGFR (IC50: 0.21, 0.16, 0.24, 1.63 and 1.72 nM, respectively)

K Nakamura et al. KRN951, a Highly Potent Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases, Has Antitumor Activities and Affects Functional Vascular Properties. Cancer Res. 2006, 66(18), 9134-9142.

Eri Taguchi et al. Anti-tumor activity and tumor vessel normalization by the vascular endothelial growth factor receptor tyrosine kinase inhibitor KRN951 in a rat peritoneal disseminated tumor model. Cancer Sci. 2008, 99(3), 623.?

C Campas et al. Tivozanib. Drugs Fut. 2009, 34(10), 793.

Certificate of Analysis
Material Safety Data Sheet

Angiogenesis Cell Signaling & Oncology VEGFR RTK class IV; EC 2.7.10.1

VEGFR1, 2, and 3 tyrosine kinase inhibitor

Chemical name

1-(2-chloro-4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-3-(5-methylisoxazol-3-yl)urea

Parent CAS No.

[475108-18-0]

產(chǎn)品資料

<button id="eiezk"><video id="eiezk"></video></button>